However, manufacturers have begun streamlining access: Novo Nordisk now offers Wegovy (semaglutide) through the NovoCare Pharmacy Program, and Eli Lilly facilitates access to Zepbound via LillyDirect, its direct-to-patient pharmacy platform
Contact your health insurance plan for more information on your costs for Zepbound or Ozempic
Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M et al
6 Emerging Options: Hormone Therapy DHEA Research has shown that the hormone dehydroepiandrosterone (DHEA) is abnormally low in patients with AMD (Bucolo 2005)
Results after an additional 48 weeks: Continued semaglutide: Additional 7.9% weight loss (17.4% total from baseline) Switched to placebo: Regained about two-thirds of lost weight This trial provides crucial evidence that Wegovy requires ongoing use to maintain results